Years of research have resulted in compounds that have been shelved for multiple reasons. The research investment therein brings down the research productivity of the organization.

If you have compounds which have been shelved due to reasons of suboptimal efficacy or unacceptable toxicity, we can help you explore their potential to bring them into productive research pipeline. We have developed robust discovery approaches that we deploy depending on the nature of the shelved compound and in short time provide you with a 'go - no go' decision.

This research is carried out by expert VLife scientists who have a sterling track record in discovery of new indications and is enabled by our computational technologies and a multi core parallel processing computational cluster.

We cover the following work-flow with the scope of engagement with client covering some or all of the following steps:

Our expertise in computational discoverySuccess with computation technology requires awareness of not only its strengths but also of the areas where it needs augmentation from other approaches. Being developers of computational technologies, we have proved our expertise by creating IP in 3 NCE classes and 7 new indication discoveries.

Wide diversity of experienceWe cater to a variety of sectors and within them, a diversity of areas. e.g. in pharmaceuticals, we have successfully delivered discovery projects in oncology, anti-fungal, diabetes, CNS etc.

State-of-art technology portfolioClients benefit from the whole range of VLife's technologies having validated algorithms, published innovations and efficient workflows which are accessible to clients through VLife services.

In-house custom development skillsGeneric technologies sometimes are inadequate or inefficient in complex research. For such needs, our in-house team has skills to develop custom technologies ensuring reliable research.